Smoothened Agonist (SAG) HCl
For research use only. Not for use in humans.
Molecular Weight(MW): 526.52
Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
Selleck's Smoothened Agonist (SAG) HCl has been cited by 16 publications
1 Customer Review
Activating Shh signaling by SAG injection in naïve mice significantly increased BDNF expression, and pretreatment with cyclopamine effectively prevented the upregulation of BDNF induced by SAG (E). Tissues were collected at 2 hours after SAG injection. Six mice were included in each group.
J Pain Res, 2018, 11:649-659. Smoothened Agonist (SAG) HCl purchased from Selleck.
Purity & Quality Control
Choose Selective Hedgehog/Smoothened Inhibitors
|Description||Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.|
SAG regulates Smo activity by binding directly to the Smo heptahelical bundle.  SAG induces Smo-dependent signaling through Gli in a GRK2-dependent way.  SAG also (1 nM) induces proliferation of neuronal and glial precursors without affecting the differentiation pattern of newly produced cells. 
|In vivo||In the adult rat hippocampus, the intracerebroventricular administration of SAG (2.5 nM) significantly increases the number of newly generated cells and extends survival of hippocampal cells.  In mice, SAG (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities. |
|In vitro||Water||100 mg/mL (189.92 mM)|
|DMSO||71 mg/mL warmed (134.84 mM)|
|Ethanol||40 mg/mL warmed (75.97 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|CAS No.||912545-86-9(free base)|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03645044||Recruiting||--||Hiv|HBV Coinfection||University of Melbourne|National Health and Medical Research Council Australia|The University of Western Australia|University of Adelaide|The HIV Netherlands Australia Thailand Research Collaboration|University of Malaya|YR Gaitonde Centre for AIDS Research and Education|Melbourne Health||May 24 2018||--|
|NCT03180619||Active not recruiting||Drug: TAF||Chronic Hepatitis B||Gilead Sciences||June 29 2017||Phase 2|
|NCT02195518||Completed||Drug: Tenofovir disoproxil fumarate||Hepatitis B Chronic||GlaxoSmithKline||March 18 2015||Phase 4|
|NCT02364336||Completed||Drug: Peginterferon alfa-2a||Chronic Hepatitis B||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)||February 14 2015||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.